The intricate metabolism of pancreatic cancers

Felipe Camelo, Quy Hoa Le Thi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Oncogenic KRAS regulates glucose and glutamine metabolism in pancreatic cancer cells.MUC1 overexpression leads to increased glucose metabolism.p53 functions predict the sensitivity of pancreatic cancer tumors to glycolytic inhibition.Targeting alpha-ketoglutarate dehydrogenase function by CPI-613 to slow mitochondrial metabolism.The antidiabetic drug, metformin, targets pancreatic cancer stem cells.Combined therapy is used to target pancreatic metabolism heterogeneity.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages73-81
Number of pages9
DOIs
StatePublished - Jan 1 2018

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1063
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Pancreatic Neoplasms
Metabolism
Ketoglutarate Dehydrogenase Complex
Glucose
Neoplastic Stem Cells
Metformin
Stem cells
Glutamine
Hypoglycemic Agents
Tumors
Cells
Neoplasms
Therapeutics

Keywords

  • Combined therapy
  • Glucose metabolism
  • Glutamine metabolism
  • KRAS mutation
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Camelo, F., & Le Thi, Q. H. (2018). The intricate metabolism of pancreatic cancers. In Advances in Experimental Medicine and Biology (pp. 73-81). (Advances in Experimental Medicine and Biology; Vol. 1063). Springer New York LLC. https://doi.org/10.1007/978-3-319-77736-8_5

The intricate metabolism of pancreatic cancers. / Camelo, Felipe; Le Thi, Quy Hoa.

Advances in Experimental Medicine and Biology. Springer New York LLC, 2018. p. 73-81 (Advances in Experimental Medicine and Biology; Vol. 1063).

Research output: Chapter in Book/Report/Conference proceedingChapter

Camelo, F & Le Thi, QH 2018, The intricate metabolism of pancreatic cancers. in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1063, Springer New York LLC, pp. 73-81. https://doi.org/10.1007/978-3-319-77736-8_5
Camelo F, Le Thi QH. The intricate metabolism of pancreatic cancers. In Advances in Experimental Medicine and Biology. Springer New York LLC. 2018. p. 73-81. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-77736-8_5
Camelo, Felipe ; Le Thi, Quy Hoa. / The intricate metabolism of pancreatic cancers. Advances in Experimental Medicine and Biology. Springer New York LLC, 2018. pp. 73-81 (Advances in Experimental Medicine and Biology).
@inbook{ef1138122d094d4aabf94f4c41af0e35,
title = "The intricate metabolism of pancreatic cancers",
abstract = "Oncogenic KRAS regulates glucose and glutamine metabolism in pancreatic cancer cells.MUC1 overexpression leads to increased glucose metabolism.p53 functions predict the sensitivity of pancreatic cancer tumors to glycolytic inhibition.Targeting alpha-ketoglutarate dehydrogenase function by CPI-613 to slow mitochondrial metabolism.The antidiabetic drug, metformin, targets pancreatic cancer stem cells.Combined therapy is used to target pancreatic metabolism heterogeneity.",
keywords = "Combined therapy, Glucose metabolism, Glutamine metabolism, KRAS mutation, Pancreatic ductal adenocarcinoma",
author = "Felipe Camelo and {Le Thi}, {Quy Hoa}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-77736-8_5",
language = "English (US)",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "73--81",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - The intricate metabolism of pancreatic cancers

AU - Camelo, Felipe

AU - Le Thi, Quy Hoa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Oncogenic KRAS regulates glucose and glutamine metabolism in pancreatic cancer cells.MUC1 overexpression leads to increased glucose metabolism.p53 functions predict the sensitivity of pancreatic cancer tumors to glycolytic inhibition.Targeting alpha-ketoglutarate dehydrogenase function by CPI-613 to slow mitochondrial metabolism.The antidiabetic drug, metformin, targets pancreatic cancer stem cells.Combined therapy is used to target pancreatic metabolism heterogeneity.

AB - Oncogenic KRAS regulates glucose and glutamine metabolism in pancreatic cancer cells.MUC1 overexpression leads to increased glucose metabolism.p53 functions predict the sensitivity of pancreatic cancer tumors to glycolytic inhibition.Targeting alpha-ketoglutarate dehydrogenase function by CPI-613 to slow mitochondrial metabolism.The antidiabetic drug, metformin, targets pancreatic cancer stem cells.Combined therapy is used to target pancreatic metabolism heterogeneity.

KW - Combined therapy

KW - Glucose metabolism

KW - Glutamine metabolism

KW - KRAS mutation

KW - Pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85049335458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049335458&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-77736-8_5

DO - 10.1007/978-3-319-77736-8_5

M3 - Chapter

C2 - 29946776

AN - SCOPUS:85049335458

T3 - Advances in Experimental Medicine and Biology

SP - 73

EP - 81

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -